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ABSTRACT  
Liquisolid technology is very effective technique for improving the solubility and dissolution properties of poorly water soluble drug 
formulations like Clotrimazole. Clotrimazole is a BCS Class II, antifungal drug used for treatment for Vaginal Candidiasis.  In this liquisolid 
technique the drug soluble in non volatile solvents and then it converted into free flowing, non adherent powder, which can be compressed into 
tablet. Here N-methyle-2-pyrrolidone and propylene glycol is used in the ratio of 1:1 as a solvent. Neusilin US2 and Aerosil 200 used as Coating 
and Carrier material respectively. For mucoadhesion on vaginal wall Sodium carboxymethyle cellulose used as a mucoadhesive agent. 
Mucoadhesive tablets were prepared using direct compression technique. Magnesium Stearate used as a glidant. Mucoadhesive liquisolid 
tablets were evaluated as precompression evalutions and post compression evaluations. Future tablets were evaluated as In vitro and Ex vivo 
evaluations. The optimized batch showed that In vitro release in simulated vaginal fluid pH 4.5 in 6 hr was 99%. Ex vivo diffusion studies of 
optimized batch showed 80% of drug diffusion in 6 hr. Mucoadhesive strength showed high mucoadhesion of optimized batch that is 36 gm. 
From this study it was concluded that liquisolid technology is an effective technique to improve solubility and dissolution properties of poorly 
water soluble drug formulations like Clotrimazole.   
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INTRODUCTION 
Vaginal candidiasis is a fungal infection which is also called 
as candida vaginitis. It develops in mucosa that usually 
causes a watery, white, cottage cheese-like vaginal discharge 
[1]. Many conventional formulations are prepared for 
treatment of vaginal candidiasis like oral and vaginal tablets. 
Vaginal drug delivery has many advantages as compared to 
oral drug delivery like bypassing the first pass metabolism 
and local drug delivery. For many years imidazole 
derivatives have been used as drugs of choice for treating 
this infection. Clotrimazole (CTZ) is BCS class II drug which 
has prominent antifungal action. It works to kill individual 
Candida or fungal cells by altering the permeability of the 
fungal cell wall. It binds to phospholipids in the cell 
membrane and inhibits the biosynthesis of ergosterol and 
other sterols required for cell membrane production. This 
leads to the cell's death via loss of intracellular elements [2]. 
CTZ is available in various formulations like tablets, creams, 
gels for local treatment. However, a major problem with 
these formulations is low residence time [3].  
Liquisolid technology is used to enhance solubility and 
dissolution of drug. In liquisolid technique the drug is 
dissolved in a suitable solvent and the liquid medication is 
loaded on solid carrier and coating material. A flowable, 
compressible powder is obtained by addition of suitable 
excipients like disintegrants, glidants and lubricants. 
Liquisolid compacts are prepared by direct compression or 
slugging method. It is cost effective technique and easy for 
industrial production [4]. Generally water insoluble or poorly 
water soluble drugs are dissolved in non volatile organic 
solvents like propylene glycol (PG), polyethylene glycols 400 
(PEG 400), N-methyle-2-Pyrrilidone (NMP) etc. These 
solvents are then loaded on various ratios of carrier and 
coating materials till a flowable, compressible powder is 
obtained. 
The aim of this study was to enhance solubility and 
dissolution rate of CTZ by liquisolid technique and 
formulation of mucoadhesive CTZ vaginal tablet using 
suitable mucoadhesive agent. A 32 factorial design was 
employed for formulation designs of batches. 
Carrier/coating material and mucoadhesive agent were the 
two independent factors selected and percent drug diffusion 
and mucoadhesive strength were selected as responses. 
Liquid Load Factor (Lf) was calculated for various 
carrier/coating ratios for selection of suitable 
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carrier/coating ratios and materials. Further liquisolid 
tablets were evaluated for precompression and post 
compression micromeritic properties, ex vivo studies and 
stability studies.  
MATERIALS AND METHODS 
Materials: 
Clotrimazole was a kind gift of Amoli organics, Vapi, India, 
Neusilin US2 also was a kind gift of Gangwal Chemicals, 
Bhiwandi India, Aerosil 200 was purchased from Analab 
Fine Chemicals, Mumbai, India, Propylene glycol, 
Polyethylene glycol 400, N-methyle-2-Pyrrilidone, Tween 
80, Tween 20 are purchased from Loba Chemicals, Mumbai, 
India. All chemical used in this study were the analytical 
grade.    
Methods 
1. Drug-excipient compatibility studies 
The IR spectrum of CTZ was recorded using FTIR 
spectrophotometer. Sample preparation involved triturating 
the mixture of sample & potassium bromide (KBr) in the 
ratio 1:50. The resultant triturate was placed in the sample 
cup and was scanned over a frequency ranging 4000-400 
cm-1. The mixtures of Neusilin US2, Aerosil 200 and sodium 
CMC with CTZ were analyzed for IR Spectra.   
2. UV-visible spectroscopy method 
A UV spectrum of CTZ was determined using methanol AR 
Grade as solvent. λmax was determined along with calibration 
curve using concentration range 10-50 µg/ml which obeys 
Beers Lamberts law [5]. 
3. Selection of non volatile solvent  
Solubility of drug in various solvents like propylene glycol, 
polyethylene glycol 400, N-methyl-2-pyrrolidone, Tween 80, 
Tween 20 was determined. An excess amount of CTZ was 
added to 10 ml of solvents in the conical flasks to prepare 
saturated solutions. These saturated solutions were 
subjected to constant shaking on incubator shaker for 48 h 
at room temperature 300 C. After shaking, the saturated 
solutions were centrifuged at 3000 rpm and supernatant 
was filtered through 0.45 μ cellulose acetate filter. Amount 
of drug in filtrate was measured using UV-VIS 
spectrophotometer at 227 nm after diluting with methanol 
[6].   
4. Determination of Flowable liquid load factor for 
carrier/coating ratios [6] [7] 
The experiment was designed to measure the flowable liquid 
retention potential (Φ-value) for Neusilin US2, 
microcrystalline cellulose (MCC), lactose, and Aerosil 200. To 
10 g of carrier/coating material, increasing amounts (0.01 
ml) of nonvolatile solvent were added and mixed well by 
triturating in glass mortar and angle of repose for powder 
was determined. The corresponding Φ-value was calculated 
from the following equation: 
  
                
                         
                                                      
     ------Equation no. (1) 
The liquid load factor (Lf) is calculated from the weight the 
liquid medication (W) and carrier powder (Q) in the system 
by following equation 
Lf = 
 
 
                        -------Equation no. (2) 
The excipient ratio (R) is the ratio of the weights of the 
carrier (Q) and the coating (q) material present in the 
formulation 
R = 
 
 
                         ------Equation no. (3) 
The liquid load factor (Lf) for acceptable flowability was 
calculated based on the Φ-value of carrier and coating 
material using following equation 
Lf = ΦCA + ΦCO(1/R)          ------Equation no. (4) 
Where,   ΦCA = Φ value for carrier material  
ΦCO = Φ value for coating material  
R= Ratio of weight of carrier to coating material 
5. Determination of amount of carrier (Q) and coating 
(q) material 
Quantity of carrier (𝑄) can be determined from using 
equation (Lf =  ⁄ ) 
Q = W/ Lf                                ------- Equation no. (5) 
Then using equation (𝑅 = 𝑄/𝑞), quantity of coating material 
can be calculated: 
q =  ⁄                                 -------Equation no. (6)                
 6. Preparation of Liquisolid tablets of Clotrimazole: 
Liquisolid compacts were prepared in three step process. In 
first step, liquid medication was prepared by dissolving 
accurately weighed CTZ in the specified amount of solvent. 
In the second step liquid medication obtained in first step 
was adsorbed on calculated amount of carrier material by 
trituration using mortar and pestle. To the obtained blend of 
liquid medication and carrier material, defined quantity of 
coating material (Aerosil 200) was added and mixed 
continuously to obtain dry powder admixture. The final 
powder blend was mixed with sodium CMC as mucoadhesive 
agent, magnesium stearate as glidant, talc as lubricant in 
mortar and pestle. The tablets were prepared using direct 
compression technique on tablet compression machine 
(Mini Press-II MT) using 10 mm punch. 
7. Statistical design: 
A 32 full factorial design was used to formulate the tablets. 
The design consisted of two factors at three levels and 
experimental trials were performed at all possible nine 
combinations. Carrier/coating material and mucoadhesive 
agent were the two independent factors selected and 
percent drug diffusion and mucoadhesive strength were 
selected as responses (Table 3). 
8. Pre compression evaluation parameters [8] [9] 
The various powder flow properties were evaluated like 
Angle of repose, Bulk density, Tapped density, Hausner’s 
ratio and Carr’s index.   
i. Angle of repose: The angle of repose for the powder blend 
was determined by fixed funnel method. Angle of repose was 
calculated using equation:    
Tan Ɵ= h/r             --------Equation no. (7)
   
Where,        h = height of powder heap in cm  
r = radius of powder heap in cm 
ii. Tapped bulk density (TBD): About 5 grams of powder 
sample was poured gently through a glass funnel into a 10ml 
graduated cylinder. The cylinder was tapped from height of 
2 inches until a constant volume was obtained. Volume 
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occupied by the sample after 100 tapping were recorded and 
tapped density was calculated as follows: 
Tapped density =    
    
             
       --------Equation no. (8) 
 iii. Bulk density (BD): Bulk density of the powder was 
determined by pouring gently 5gms of sample through a 
glass funnel into a 10ml graduated cylinder. The volume 
occupied by the sample was recorded. The bulk density was 
calculated as follows: 
Bulk density =     
    
           
              -------Equation no. (9) 
iv. Carr’s Compressibility Index (CI): The compressibility 
index of the powder blend was determined using Carr’s 
compressibility index: 
   
                             
                   
         -----Equation no. 
(10)                         
v. Hausner ratio: Hausner ratio was determined for 
characterization of flow of powder blend. A Hausner ratio 
greater than 1.25 is considered to be an indication of poor 
flowability. Formula used was as follows:  
Hausner Ratio=
                 
            
     -  ------Equation no. (11) 
11. Post Compression Evaluations  
i. Hardness and thickness 
The resistance of tablets to shipping or breakage under 
conditions of storage, transportation and handling before 
usage depends on its hardness. The hardness of tablet of 
each formulation was measured by Monsanto hardness 
tester (Nevtex). The hardness was measured in terms of 
kg/cm2. [10] Thickness and diameter of tablets were 
important for uniformity of tablet size. Thickness and 
diameter were measured using digital Vernier Caliper 
(Swastik, Mumbai).  
ii. Friability 
Friability is the measure of tablet strength. Roche friabilator 
(Veego, Mumbai) was used for testing the friability using the 
following procedure. Ten tablets were weighed accurately 
and placed in the tumbling apparatus that revolves at 25 
rpm dropping the tablets through a distance of six inches 
with each revolution. After 4 min., the tablets were weighed 
and the percentage loss in tablet weight was determined. [11] 
iii. Uniformity of weight  
Twenty tablets were weighed randomly and average weight 
was calculated. Not more than two of the individual weights 
deviate from the average weight by more than the 
percentage shown in table and none deviates by more than 
twice that percentage. 
 iv. Determination of drug content  
Twenty tablets of each batch were randomly selected, 
weighed and powdered. The quantity of powder equivalent 
to 25 mg of CTZ was taken and dissolved in 10 ml of 
methanol and filtered [12]. The absorbance was measured 
spectrophotometrically at 227 nm after suitable dilution.  
12. In vitro dissolution studies 
The in vitro dissolution studies were carried out using USP 
apparatus type II (DA 8000, Labindia) at 50 rpm. The 
dissolution medium was 500 ml of simulated vaginal fluid 
maintained at 37°C ± 0.5°C. Aliquots of 5 ml were withdrawn 
at 1 h interval till 6 h. The aliquots were then analyzed by UV 
spectrophotometer at 227 nm [13]. 
13. Determination of mucoadhesive strength: 
Mucoadhesive strength was evaluated using a Texture 
Analyzer (CT 3 Texture Analyzer, Brookfield Engineering 
Labs, Inc., Model Texture Pro CT V1.4 Build 17). Fresh sheep 
vaginal mucosa was obtained from a local slaughter house 
and was used within 2 h of slaughtering. The mucosal 
membrane was washed with distilled water and then with 
acetate buffer pH 4.6, subsequently it was carefully attached 
to a 10-mm cylindrical probe (TA 3/100probe) using a 
double-sided adhesive tape. The upper platform was moved 
downward manually near to the tablet surface and then the 
mucosa was brought toward the tablet at a constant speed of 
1mm/s until a predetermined compressive force of 0.5 N was 
applied with holding time of 60 s and load cell of 1000 gm. 
The probe was then removed with return speed of 1 mm/s 
to a distance of 15 mm and maximum detachment force (g) 
was determined for each sample with data rate 15 
points/sec. For each new sample, a different mucosa sample 
was used [2]. 
14. Optimization and validation model  
The response from the release data and mucoadhesive force 
was fed to the Design expert software 11.0 and polynomial 
equations were generated. Numerical optimization was done 
using desirability function and predicted formula was 
prepared and analyzed to test whether the result matches 
predicted results by DOE. 
15. Ex- vivo diffusion studies 
Ex vivo drug permeation studies of the drug through the 
sheep vaginal membrane was performed using Franz 
diffusion cell at 37°C ± 0.2°C. Fresh sheep vaginal tissue was 
mounted between the donor and receptor compartments. 
The optimized vaginal tablet was placed with the core facing 
the tissue and the compartments clamped together. Both 
donor and receptor compartments were filled with 8 ml of 
simulated vaginal fluid (pH 4.5) and stirred with magnetic 
bead at 50 rpm. Samples of 1 ml were withdrawn every hour 
(up to 6 h) and analyzed for drug content at 227 nm using an 
ultraviolet-visible spectrophotometer [14].  
16. Swelling Index 
Optimized vaginal tablets were weighed individually (𝑊1) 
and placed separately in petri dishes containing 4 ml of 
simulated vaginal fluid (pH 4.5) solution. At regular intervals 
(1, 2, 3, 4, 5 and 6 h), the tablets were removed from the 
petri dishes and excess surface water was removed carefully 
using filter paper [15]. The swollen tablets were then 
reweighed (𝑊2) and swelling index (SI) was calculated 
using the following formula: 
Swelling Index = (𝑊2−𝑊1)/𝑊1*100      ----Equation no. (14) 
17. Stability studies 
The optimized formulation was subjected to stability studies 
at 40°C / 75% Relative Humidity (RH) for 45 days. Samples 
were withdrawn at 15-days time interval and evaluated for 
physical properties, drug content and drug dissolution [16]. 
RESULTS AND DISCUSSION 
1. Drug-excipient compatibility studies 
This test was carried out to check the interaction of drug and 
excipients. The FT-IR spectra of CTZ shows the absorption 
band at 1440 cm-1, 1590 cm-1, 1674 cm-1 due to C-N 
stretching, N-H bending and C=O stretching of primary 
amide group. It is further noted that out of plane N-H 
wagging, C-N stretching vibrations, N-H bending, free 
asymmetric and symmetric N-H stretching vibrations 
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appears at 750 cm-1, 1208 cm-1 and 3062 cm-1, respectively. 
Absorption bands at 455 cm-1, 1091 cm-1 are assigned due to 
out of plane C=C bend and in plane C-H bend. It can be seen 
that absorption bands in the range of at 2229-2638 cm-1 are 
due to methyl C-H stretching. By comparing the spectra of 
CTZ and its physical mixture, it was observed that all the 
peaks lie in their appropriate range. No changes were 
observed which indicated there was no interaction between 
CTZ and excipients. 
2. Selection of non volatile solvent 
Solubility data of drug CTZ was determined in 1:1 ratios of 
various non-volatile liquid vehicles. CTZ was found be more 
soluble in NMP:PG liquid than other liquids. CTZ found to 
have very less solubility in water. The solvent selection for 
preparation of liquisolid powder is also determined by high 
solubility of drug in solvent. Hence the NMP:PG was selected 
as a solvent as the solubility of drug in this solvent is high 
(Fig. 2). NMP and PG are miscible with water have good 
solubilizing properties [17][18][19].    
3. Determination of flowable liquid load factor for 
carrier/coating ratios 
The ΦCA-value and ΦCO-value decide the amount of carrier 
and coating materials required to produce dry, non 
adherent, free-ﬂowing and readily compatible liquisolid 
formulations. Hence, determination of the ﬂow  properties of 
powder excipients and liquid/powder admixtures is an 
important step to produce a successful liquisolid 
formulation. MCC, lactose, Neusilin US2, and Aerosil 200 
were examined as carrier and coating materials for 
preparing liquisolid tablets. Ratios of MCC/Aerosil, 
lactose/Aerosil showed high liquid load factors but they 
exhibited poor flowability. On the other hand 
Neusilin/Aerosil ratios showed less liquid load factor but the 
angle of repose indicated good flowability of powder (Table 
3). 
4. Preparation and evaluation of liquisolid tablets of CTZ 
A 3 – Level Factorial Design (32) was employed for the 
optimization of liquisolid formulation. The levels of were 
varied as 5, 12.5, 20 of factor 1 (carrier: coating ratio) and 12 
mg, 19 mg, 27 mg of factor 2 (amount of mucoadhesive 
agent). The data obtained clearly shows that responses are 
strongly dependent on the independent variables. The 
experimental batches were optimized using Design Expert 
Software version 11.0. The 9 batches predicted by the 
optimization software (Table 5) were analyzed for 
responses such as % drug diffusion (%) (A) and 
mucoadhesive force (g) (B). Table no. 4 shows liquid load 
factor and quantities of carrier (Q), coating material (q) and 
the weight of liquid medication (W).The liquid load factor of 
different ratios of Neusilin US2® and Aerosil 200® were 
found to be conducive for good flowability of powder. Their 
high carrier: coating ratios showed high liquid load factor. 
5. Statistical analysis of 32 full factorial design for 
formulation of liquisolid compacts 
Using Design Expert® Software version 11 (Stat-Ease, Inc., 
Minneapolis, USA), statistical experimental design for 32 
factorial design was evaluated. The values of examined 
responses obtained for all trial formulations were fitted in 
the 32 factorial design to get model equations for responses 
analyzed. Quantitative effect of independent variables in the 
obtained equation were mean results obtained by changing 
one factor from its low to high value keeping another factor 
constant. Response surface methodology is a widely used 
approach for the development and optimization of 
formulation variables. The polynomial equation obtained 
was visualized with the help of 3D response surface graphs. 
i. Ex vivo drug diffusion in 6h 
The independent factor (A) that is carrier/coating ratio 
showed positive effect on diffusion of drug through vaginal 
tissue. As the carrier: coating ratio increases diffusion of 
drug also increases which may be because of liquid being 
loaded on carrier and on coating material. The low particle 
size of the carrier (Neusilin: 60-100 µm) and coating 
materials (Aerosil: 100 µm) provides larger surface area for 
adsorption of the liquid thus enabling uniform, thin film of 
the liquid on the particle surfaces. Factor B (concentration of 
mucoadhesive agent) did not have a significant effect on 
percent diffusion. As per ANOVA the p-value is 0.0014, p-
value less than 0.0500 indicated quadratic model terms 
were significant. The Model F-value of 105.05 also implied 
the model was significant. In 3D graph (Fig 3) the highest 
point indicates that the F6 batch which showed highest 
carrier: coating ratio and highest amount of mucoadhesive 
agent that is sodium CMC. So by this batch results there 
might be high diffusion and high mucoadhesion. 
Percent Diffusion=  
+66.30+14.33A-0.9300B+3.61AB+2.18A2-1.12B2         
----Equation no. (1) 
As per the data of ex vivo % diffusion of CTZ (Table  5), F8 
batch showed 80% diffusion while F6 batch showed 87.59% 
diffusion on sheep vaginal tissue in 6 h. F1 batch showed 
lowest diffusion that is 50%.  F6 batch has high 
carrier/coating ratio may be because it F6 batch showed 
more drug diffusion. From the results it can be concluded 
that there was a direct relationship between the powder 
excipient ratio (R) and the release of drug from liquisolid 
tablets, when R value increases, the release rate will also 
increase. The ex vivo % drug diffusion graph indicates high 
% drug diffusion of F6 batch due to its high Neusilin 
US2®/Aerosil 200® ratio. High amount of liquid medication 
adsorbed on this ratio hence more % drug diffusion may be 
showed by the results. 
ii. Mucoadhesive strength 
The following equation was statistically significant and 
followed the quadratic model. 
Mucoadhesive Strength =  
+18.97-0.5200A+0.6767B+0.8025AB-2.10A2+14.12B2    
---Equation no. (2) 
The concentration of mucoadhesive agent (B) had an 
obvious positive effect on mucoadhesive strength. As the 
amount of mucoadhesive agent increases the mucoadhesion 
strength also increases. This also indicates that the powder 
mixture of carrier and coating material did not significantly 
impact the mucoadhesive strength of the tablets. The 
equation showed that mucoadhesive agent showed positive 
effect on mucoadhesion and negative effect on diffusion of 
drug. As per ANOVA for mucoadhesion response the p-value 
was 0.0026, p-value less than 0.0500 showed model terms 
significant. The Model F-value of 71.05 implied the 
significance of quadratic model. In this 3D graph (Fig. 5) the 
highest point showed that the batch F6 showed the high 
quantity of carrier: coating ratio and high quantity of 
mucoadhesive agent that is sodium CMC.  
As shown in (Table 5) the high mucoadhesive agents 
concentration indicated stronger mucoadhesion on sheep 
vaginal tissue. Sodium CMC is anionic polymer which forms 
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strong hydrogen bonds with mucin hence attachment to the 
mucosal layer is strong [14]. Additionally the polymer chains 
of the polymer interpenetrate the mucin lining the mucosal 
membrane giving better mucoadhesivity.  
6. Characterization of factorial batches 
i. Precompression evaluations 
Liquisolid admixtures for CTZ were prepared according to 32 
full factorial design taking different Lf values. The physical 
characteristics of flow properties such as angle of repose, 
Carr’s index and Hausner ratio can help in analysing 
compressibility and flowability of Liquisolid admixtures. 
Liquisolid powders with an angle of repose (θ°) in the range 
of 25°–35° were considered as powders possessing 
acceptable flow properties. Moreover, powders having Carr’s 
index (C %) below 15 were considered to have good flow 
properties and could be successfully compressed into tablets 
with uniform weight. Powders with low interparticle friction 
having Hausners ratio less than or equal to 1.18, indicated 
good flow. Adsorption of liquid medication on 
carrier/coating material can greatly influence angle of 
repose of liquisolid admixture. 
ii. Post compression evaluations 
All liquisolid tablets formulated were subjected to post 
compression parameter studies as showed in (Table 7). The 
thickness of tablet was increased by an increase in the 
weight of the tablet. The hardness of all the tablets was 
observed in the range of 3-5 kg/cm2 depending on excipient 
concentration. Uniform drug content was observed for all 
these formulations as per the IP specification (90-110%). 
The friability of the tablets was within the limit, and slight 
variation in friability was because of the difference in 
compression force applied and total weight. 
iii. In vitro dissolution studies 
As per dissolution studies data showed in (Fig.6), the 
carrier/coating ratio has been shown to affect the 
dissolution rate. The increase in carrier coating ratio showed 
an increase in drug dissolution rate which might be because 
of the presence of more amount of Neusilin in those 
formulations which have liquid medication adsorbed on it. 
F1 batch showed more than 80% cumulative drug release. 
F8 batch showed drug release of about 94 % while F9 batch 
showed high cumulative drug release upto 97% in 6 h. F6 
batch showed highest cumulative drug release of 99%.  F6 
batch has high ratio of Neusilin US2® and Aerosil 200® 
which thereby has higher liquid load factor. A higher carrier- 
coating ratio indicates presence of larger quantity of the 
carrier material (Neusilin) than coating material (Aerosil).           
iv. Swelling Index (SI) of factorial batches 
Liquisolid tablets were placed in simulated vaginal fluid pH 
4.5. At regular intervals (1, 2, 3, 4, 5 and 6th hour) tablets 
were removed from the petri dishes. Swollen tablets were 
reweighed and calculated for SI. The 6th hr results indicated 
percent swelling index as showed in (Fig. 7). As 
concentration of mucoadhesive agent increased the swelling 
also increased. There was slow and gradual increase in 
swelling of vaginal tablet as it got in contact with simulated 
vaginal fluid pH 4.5. The mucoadhesion is a function of 
swelling index of the polymer. The swelling polymer forms a 
matrix with channels through which the drug diffuses 
uniformly. 
7. Selection and validation of optimized batches 
Selection of optimized formulation of liquisolid tablets was 
carried out; where the various trials were made to attain the 
goals like maximization of percent drug diffusion of CTZ in 
vaginal tissue and maximization of mucoadhesion of tablet. 
The optimize batch was chosen by numeric optimization 
using the desirability function. The constraints set for 
numerical optimization of liquisolid tablet formulation 
included percent drug diffusion (A) and mucoadhesion (B). 
Based on these two responses (A and b), there were three 
different optimized batches of liquisolid formulation given 
by the software and among these three different batches of 
liquisolid tablet, one batches selected as an optimized batch 
of liquisolid tablet based on their desirability function. 
Validation of the optimization methodology by comparing 
the observed responses with those of the predicted response 
understood that percent prediction error for both the 
responses (A and B) ranging between 1.13% and 0.44% of 
liquisolid tablet formulation. Thus, the formulation batch 
giving the maximum percent drug diffusion of formulation 
and maximum mucoadhesion chosen as the optimized batch. 
Design expert software gave 3 batches with response results. 
Then results were compared to actual experimental results 
value and % predicated error is calculated. The statistically 
optimized formulation of CTZ Liquisolid Compacts (O1) 
fulfilled all the physicochemical criteria. The relative errors 
(%) between the predicted and experimental values for each 
response were calculated and the values found to be within 
5%. The experimental values were in agreement with the 
predicted values confirming the predictability and validity of 
the model. Based on the results obtained formula for 
optimized liquisolid compacts following formulation 
variables were considered as optimized and formula for 
optimized batch is given in (Table 5). 
8. Stability studies 
The optimized formulation (F-6) was subjected to stability 
studies at 40°C / 75% RH for 45 days. Samples were 
withdrawn at 15-days of time intervals and evaluated for 
physical properties, drug content and drug dissolution. 
Results showed that on 45th day 98.65% ±2.18 drug content 
available in formulation and hence this change did not show 
any significant changes during stability studies. And also this 
study showed no change in drug dissolution. 
CONCLUSION 
The complete summary of present work concludes that the 
Liquisolid technique is good method for improving 
dissolution of poor water soluble drug. The results obtained 
from 32 factocrial design in this study suggest that Neusilin 
US2: Aerosil 200 ratio (20) and Sodium CMC (27 mg) is the 
best formulation. The optimize batch showed acceptable 
values of precompression and post compression parameters. 
The liquisolid compacts of optimized formula were 
successfully compressed without any difficulties. The 
prepared compacts showed improved dissolution. 
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Fig 1. FTIR spectra (after 30 days) for drug-excipient compatibility studies. 
Drug and Sodium CMC (A), drug and Neusilin (B), drug and Aerosil 200 (C) 
 
Fig 2: Solubility of Clotrimazole in different solvents 
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Fig 3: Response surface plot for % diffusion of Clotrimazole 
 
Fig.4 Ex vivo % drug diffusion of CTZ in 6h 
 
Fig 5: Response surface plot of mucoadhesion of Clotrimazole 
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Fig 6: In vitro drug release of CTZ in 6h 
 
Fig 7. Swelling index of batches F1-F9 
           Table 1:  Actual & coded levels of the factors 
Factor Actual values Coded values 
low Mid High Low Mid High 
Factor A   Excipient ratio 5 12.5 20 -1 0 1 
Factor B   Sodium CMC 12 mg 18 mg 27 mg -1 0 1 
                         
                              Table 2: Solubility data of Clotrimazole in different solvent Data expressed as mean±SD (n=3) 
Sr.no                Solvents Soluble concentration(mg/ml) 
1 Water 0.00387±0.00257 
2 Simulated Vaginal Fluid pH 4.5 0.1719±0.0644 
3 NMP: PG 19.96±0.6 
4 Tween 80: PEG 400 2.2±1.7 
5 Tween 20: PG 1.83±0.51 
6 PEG 400: Tween 20 2.1±1.1 
 
Table 3: Flowable Liquid Retention Potential (Φ- value) 
Carrier/Coating 
materials 
Ratios Angle of 
repose (Ɵ0) 
Liquid retention 
Potential of Carrier 
(ΦCA- value) 
Liquid retention 
potential of Coating 
material    (ΦCO- value) 
Liquid Load 
Factor (Lf) 
MCC/Aerosil 
 
 
5 45.23 0.22 4.23 0.8901 
10 44.24 0.29 5.11 0.5400 
15 40.11 0.35 5.88 0.4153 
20 39.96 0.41 6.01 0.3210 
Lactose/Aerosil 
 
 
5 32.21 0.21 4.11 0.8640 
10 35.62 0.29 4.66 0.4950 
15 40.66 0.35 5.12 0.3646 
20 40.74 0.48 5.33 0.2905 
Neusilin/Aerosil 
 
5 29.12 0.41 1.75 0.4320 
10 27.32 0.34 4.09 0.4430 
15 26.11 0.44 6.55 0.4660 
20 29.33 0.75 8.88 0.4815 
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Table 4: Formulation design of factorial batches 
Batches Drug 
(mg) 
Liquid Load 
Factor (Lf) 
Amount of 
Carrier (Q) 
(mg) 
Amount of 
Coating material 
(q) (mg) 
Weight of 
Liquid (W) 
(mg) 
Magnesium 
Stearate (mg) 
Talc 
(mg) 
Total 
weight 
(mg) 
F1 25 0.2655 83.48 16.69 131.57 10 5 271.74 
F2 25 0.3449 231.96 18.55 131.57 10 5 422.08 
F3 25 0.2655 83.48 16.69 131.57 10 5 271.74 
F4 25 0.3449 231.96 18.55 131.57 10 5 422.08 
F5 25 0.3449 231.96 18.55 131.57 10 5 422.08 
F6 25 0.5672 381.47 19.07 131.57 10 5 572.11 
F7 25 0.2655 83.48 19.69 131.57 10 5 271.74 
F8 25 0.5672 381.47 19.07 131.57 10 5 572.11 
F9 25 0.5672 381.47 19.07 131.57 10 5 572.11 
 
                  Table 5: 32 Statistical design for formulation of liquisolid compacts Data expressed as mean±SD (n=3) 
 Factor 1 Factor 2 Response 1 Response 2 
Batches A:Carrier:coa
ting ratio 
B: Mucoadhesive 
agent. Na-CMC(mg) 
% Diffusion 
(%) 
Mucoadhesion 
(gm) 
F1 5 27 50.3±3.33 36.23±2.9 
F2 12.5 12 71.27±5.1 32.15±3.2 
F3 5 19 69.61±2.3 20.56±4.4 
F4 12.5 19 67.06±3.6 20.03±5.5 
F5 12.5 27 68.24±1.9 32.96±2.3 
F6 20 27 87.59±4.1 36.3±3.7 
F7 5 12 50.20±3.6 36.21±2.9 
F8 20 19 80.58±4.5 20.51±5.5 
F9 20 12 79.71±3.9 33.07±4.5 
 
Table 6: Precompression Evaluation liquisoild powder of factorial batches Data expressed at Mean±SD (n=3) 
Batches Bulk Density 
(gm/ml) 
Tapped Density 
(gm/ml) 
Hausners 
Ratio 
Carrs Index 
(%) 
Angle of Repose 
(θ°) 
F1 0.21±0.1 0.23±0.13 1.09±0.68 8.70±4.5 33±3.52 
F2 0.24±0.57 0.26±0.15 1.08±0.2 7.59±3.5 30.12±2.41 
F3 0.26±1.57 0.28±0.16 1.07±0.22 6.97±5.10 27.3±3.54 
F4 0.21±0.1 0.23±0.15 1.06±0.89 7.07±4.63 28.25±2.66 
F5 0.25±0.12 0.26±0.12 1.06±0.65 6.31±2.63 30.26±3.12 
F6 0.21±0.13 0.22±0.16 1.09±0.66 8.70±4.45 26.14±5.5 
F7 0.23±0.14 0.25±0.15 1.08±0.96 7.89±3.89 27.17±5.12 
F8 0.25±0.16 0.27±0.16 1.07±0.85 7.31±4.78 30.17±3.33 
F9 0.26±0.13 0.28±0.18 1.05±0.64 5.91±2.12 26.56±5.23 
 
Table 7: Post Compression Study of Factorial Batches Data expressed at Mean±SD (n=3) 
Batches Hardness 
(Kg/cm2) 
Friability (%) Thickness (mm) Weight Variation  Drug Content (%) 
F1 4.33±1.22 0.5882±1.23 4.19±1.36 351.07±0.607 97.69±1.12 
F2 4.6±1.54 0.5376±2.33 5.57±1.22 434.08±0.756 96.66±2.12 
F3 3.86±2.56 0.4040±3.45 4.0±1.45 343.40±0.590 97.58±2.41 
F4 4.46±1.52 0.3076±2.11 5.47±1.98 441.74±0.751 95.54±3.66 
F5 3.73±2.23 0.3267±4.23 5.53±2.12 449.41±1.97 97.79±2.41 
F6 4.78±1.29 0.3125±2.56 5.71±2.13 705.65±0.524 98.16±1.45 
F7 4.55±1.89 0.4166±3.77 4.0±1.45 335.74±0.512 96.66±3.55 
F8 4.21±1.65 0.2666±4.65 5.31±1.33 697.41±0.716 97.79±2.25 
F9 3.64±2.56 0.3333±2.56 5.11±2.02 670.09±0.489 96.56±4.45 
 
 
